Navigation Links
Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Date:8/28/2007

Completion of Adult Trial Enrollment follows FDA approval of Zingo in

Children

SOUTH SAN FRANCISCO, Calif., Aug. 28 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that it has completed enrollment of the Phase 3 clinical study of Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system to reduce pain associated with peripheral venous access procedures in adults. Zingo, a fast-acting topical, needle-free system for local analgesia, was approved by the U.S. Food and Drug Administration (FDA) on August 16, 2007 to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children ages three to 18. Anesiva expects to announce results from the adult trial in October.

"Our goal is to utilize the data from this Phase 3 study to file a supplemental new drug application for the use of Zingo in adults," said John P. McLaughlin, chief executive officer of Anesiva. "In addition, we look forward to providing more detail on the commercialization of Zingo in the approved indication for children in the coming weeks."

Venous access procedures, such as IV insertions and blood draws, are among the most common interventions performed in hospitals, with more than 400 million such procedures performed each year in U.S. hospitals.

The Phase 3 study of Zingo in adults enrolled 699 patients undergoing intravenous cannulation or venipuncture procedures at multiple clinical centers in the U.S. Patients were randomized to receive treatment with either Zingo or placebo approximately one to three minutes prior to the peripheral venous access procedure.

About Zingo

Zingo is a ready-to-use
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... Inc. (NYSE MKT: IG), a New Jersey based specialty generic ... the second quarter ended June 30, 2014. Second ... million in the second quarter of 2014, an increase of ... revenues of $13.3 million for the six months ended June ... in 2013 , Total revenues generated from the sale ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/24/2014)... 2014 Ticket Down is a reliable ... Denver at the Sports Authority Field on July 26th. For ... Challenge) has brought some of the best club teams from around ... Cup still being raved about weeks after its completion, fans – ... some of the biggest stars in the world compete. Some of ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... York (PRWEB) July 24, 2014 ... ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District ... protective order for plaintiff medical information covered by ... According to the July 16th Order, U.S. District ... for Fresenius Medical Care the right to ...
(Date:7/24/2014)... 24, 2014 In a July 9th article ... founder of Lotus Blossom Consulting LLC , was quoted ... Three Ways to Cut the High Cost of Infertility . ... costs is to maximize your chance of success from the ... a clinic. , “I am always happy to talk ...
(Date:7/24/2014)... of Association Executives (ASAE) announced its 2014 Power of ... American Society of Anesthesiologists (ASA). , The ASA ... A Gold Award, one of the top honors from ... of the world through education on the global anesthesia ... care. , ASA was also honored with a Power ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
... Computer Sciences,Corporation (NYSE: CSC ) today ... to,a global information technology (IT) applications management ... the five-year agreement, CSC will continue to ... Sun,s business,applications portfolios -- including finance, manufacturing, ...
... National Institute of Environmental Health Sciences (NIEHS), part ... a total of $6.8 million for the first ... called DISCOVER - Disease Investigation Through Specialized Clinically-Oriented ... are expected to bridge the gap between basic ...
... Company Returns to Commercial Operations, SEATTLE, Dec. ... today announced that it has completed its,acquisition of ... responsibility for marketing, sales, and development of the ... be sold outside the United,States by Bayer Schering ...
... to hay fever and other allergic reactions, by preventing ... discovered by scientists. Researchers hope their finding, published today ... will allow therapies to be developed that treat allergies ... that a gene known as GATA-3 can block the ...
... vessels that supply tumors slows the progression of ... large clinical trial of Avastin, an anti-angiogenic therapy. ... of the New England Journal of Medicine, found ... progression-free survival for women with breast cancer compared ...
... While study results are promising, they don,t address benefits ... -- A treatment that wipes out abnormal heart tissue ... have defibrillators implanted after heart attacks, a new trial ... going when it slips into abnormal rhythms, they are ...
Cached Medicine News:Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:NIEHS awards DISCOVER grants 2Health News:NIEHS awards DISCOVER grants 3Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 2Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 3Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 4Health News:Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States 5Health News:Fight against hay fever and other allergies helped by new immune system discovery 2Health News:Bevacizumab found to improve survival for patients with advanced breast cancer 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: